As part of our neurobiology services platform, WuXi AppTec offers a comprehensive panel of advanced technologies and validated disease models to help project teams overcome the challenges in predicting the efficacy and safety of their lead candidates. • 200+ neurological preclinical models: comprehensive capabilities in neuropharmacology • Full-spectrum neurological coverage: from neurodegenerative diseases and neuropsychiatric disorders …Read More >

High throughput experimentation (HTE) is frequently employed to identify reaction conditions for challenging transformations, giving access to a diverse array of medicinal chemistry targets. In parallel to using conventional batch reactions, we also incorporate flow chemistry into early phase synthesis to help with reaction selectivity and optimization, up-scaling, and solving specific chemical problems. In this …Read More >

Introduction: Diabetes is a chronic, metabolic disease resulting from defects in insulin secretion and varying degrees of insulin resistance. Early symptoms include increased thirst and urination, increased hunger, and blurred vision. Progressively, complications such as cardiovascular disease, peripheral neuropathy, nerve damage, myocardial disease, and kidney disease may occur. The prevalence of diabetes at younger ages …Read More >

In the last decade, targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific disease-related proteins using cellular self-destruction mechanisms. WuXi AppTec has built a robust TPD discovery platform, allowing for in-depth biological and biophysical characterization of monovalent (molecular glue) and bivalent (PROTAC®) molecules through the use of target …Read More >

WuXi AppTec offers a comprehensive platform of in silico drug discovery services to accelerate the process of hit finding and hit-to-lead optimization.  We provide access to virtual chemical spaces built from our library of novel drug-like scaffolds, to support virtual screening and structure-based virtual screening (SBVS). Advances in ML-empowered virtual screening allows project teams to …Read More >

An inevitable challenge emerges over time as tumors develop drug resistance, resulting in treatment failure.  The development of targeted therapies for overcoming drug resistance represents an unmet medical need. Patient-derived xenografts (PDXs) represent a powerful platform for cancer drug screening and biomarker discovery and are considered the gold standard of in vivo models for their …Read More >

OncoWuXi Express: Evaluation of DLL3 CAR-T in SHP-77-Luc Tumor Models  Introduction: OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we showcase our DLL3 CAR-T cell preparation and evaluation of their anti-tumor …Read More >

Benefiting from 15 years of expertise in protein production, the Protein Science platform in WuXi Biology has successfully served hundreds of global clients. Our protein science specialists at the Munich and Suzhou sites are at the forefront of international drug discovery efforts, offering a wide range of services, including protein production and various techniques of …Read More >

In addition to identifying chemical starting points for early drug discovery processes, DNA-encoded library (DEL) technology has now expanded to new applications, including the discovery of bifunctional affinity ligands historically considered difficult to develop. At the 2024 Gordon Research Conference, WuXi AppTec presented a poster describing how DEL can enable the rapid discovery of novel …Read More >